Prevention and Treatment of Re -stenosis after PTA in Rabbit with Xuefu Zhuyu Concentrated Pills

doi:10.13288/j.11-2166/r.1997.11.028

您当前的位置：

首页 >

文章列表页 >

Prevention and Treatment of Re -stenosis after PTA in Rabbit with Xuefu Zhuyu Concentrated Pills

更新时间：2021-11-20

- Prevention and Treatment of Re -stenosis after PTA in Rabbit with Xuefu Zhuyu Concentrated Pills
- Journal of Traditional Chinese Medicine Issue 11, Pages: 685-687(1997)
- 作者机构：
  
  1. 中国中医研究院西苑医院心血管病研究室
  2. 北京医科大学第三临床医学院心血管内科
  3. 北京医科大学第三临床医学院心血管内科北京海淀区西苑,100091
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.1997.11.028
  CLC： R285.5
- Published：1997
- 稿件说明：
移动端阅览
[1]史大卓,徐风芹,马晓昌,李立志,汪小芳,陈可冀,李平,毛节明,陈明哲,韩启德.血府逐瘀浓缩丸防治家兔经皮血管腔内成形术后再狭窄的研究[J].中医杂志,1997(11):685-687+644.

Prevention and Treatment of Re -stenosis after PTA in Rabbit with Xuefu Zhuyu Concentrated Pills[J]. Journal of Traditional Chinese Medicine1997, (11): 685-687.
[1]史大卓,徐风芹,马晓昌,李立志,汪小芳,陈可冀,李平,毛节明,陈明哲,韩启德.血府逐瘀浓缩丸防治家兔经皮血管腔内成形术后再狭窄的研究[J].中医杂志,1997(11):685-687+644. DOI： 10.13288/j.11-2166/r.1997.11.028.

Prevention and Treatment of Re -stenosis after PTA in Rabbit with Xuefu Zhuyu Concentrated Pills[J]. Journal of Traditional Chinese Medicine1997, (11): 685-687. DOI： 10.13288/j.11-2166/r.1997.11.028.

摘要

本实验采用家兔髂动脉粥样硬化模型

研究血府逐瘀浓缩丸（简称浓缩丸）对经皮血管腔内成形术（PTA）后再狭窄的影响

结果显示:PTA后4周家兔髂动脉管腔直径

浓缩丸大剂量组明显大于空白对照组和美降脂组（P<O.01和P<O.001）;血管病变再狭窄率

浓缩丸大剂量组与空白对照组相比明显降低（P<0.005）;髂动脉内膜厚度

浓缩丸大剂量组明显小于美降脂组和空白对照组（P<0.01～0.001）;透射电镜观察

浓缩丸大小剂量组血管平滑肌细胞（VSMC）内细胞器少

含有肌丝

分化较好

空白对照组、美降脂组细胞内细胞器多

处于增殖状态;四组PTA后4周血脂水平没有显著性差异。

Abstract

Rabbit model of arteriosckrosis of iliac artery was used in this experiment. Results showed: after 4 weeks of PTA operation

the calibre of the artery in large dose concentrated pill （LCP） group was obviously larger than that of the western drug group and Lovastatin group （P<0. 01 andP<0. 001）. For the rate of restenosis at the site of vessel lesion

the LCP group was obviously lower than that of the blank control group （P<0. 005）. For the thickness of iliac arterial intima

the LCP group was markedly smaller that of the Lovastatin and blank control groups （P<0. 01-P < 0. 001）. By transmission electro - microscopic observation

the organelle in the vascular smooth muscle cells in LCP and small - duo group contained myofilaments well differentiated

while those in the Lovastatin and blank control groups were much more and in proliferated condition. The level of blood lipids in all 4 groups A weeks after PTA operation showed no significant difference.

关键词

Keywords

references

查看原文

Views

118

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy and Economic Evaluation of 1293 Non-Severe Adult Patients with Community-Acquired Pneumonia Treated by the Jiangsu Traditional Chinese Medicine Diagnosis and Treatment Protocol for Dominant Diseases：A Multicenter，Retrospective Real-World Cohort Study

Exploring the Comorbidity Mechanism，Prevention and Treatment Strategies of Rheumatoid Arthritis with Coronary Atherosclerotic Heart Disease Based on Collateral Disease Theory

Current Status and Strategic Recommendations for Randomized Controlled Trials on Functional Dyspepsia-Irritable Bowel Syndrome Comorbidity：from a Real-World Research Perspective

WANG Qingguo's Experience in Treatment of Headache Based on the Concept of "Achieving Harmony by Unblocking and Balancing"

Efficacy and Economic Evaluation of Weishi Qingjin Formula （苇石清金方）in the Treatment of Adult Community-Acquired Pneumonia with Phlegm-Heat Obstructing the Lung Syndrome：A Multicenter Retrospective Real-World Cohort Study

Related Author

No data

Related Institution

No data

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰